Treatment of Functional Dyspepsia in Helicobacter pylori Infection

Patients with functional dyspepsia (FD) and confirmed Helicobacter pylori infection represent a specific clinical sub-population where management addresses both the organism and persistent dyspeptic symptoms.

Clinical scenario

H. pylori-positive functional dyspepsia is a well-characterised situation in which eradication of the organism is recognised as an efficacious treatment strategy. Active infection should be confirmed before selecting the management approach.

Treatment approach — partial overview

Alongside addressing the infection, acid suppression therapy — using either a proton pump inhibitor (PPI) or a histamine-2-receptor antagonist (H2RA) — is a component of symptom management, with evidence supporting use of the lowest effective dose.

The complete structured regimen, sequencing, and full clinical considerations are available in the protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/gutjnl-2022-327737

Eradication therapy is an efficacious treatment for H. pylori-positive patients with FD.
However, there is evidence that acid suppression therapy with H2RAs or PPIs is beneficial.
PPIs are an efficacious treatment for FD. There does not appear to be a dose response, so the lowest dose that controls symptoms should be used.
Histamine-2-receptor antagonists may be an efficacious treatment for FD.

View source ↗